Chong Kung Dang Pharmaceutical (KRX:185750) reaffirmed its plans for a 2.2 trillion won biopharma R&D complex in Siheung's Baegot district, after it was named a preferred negotiating partner for the site in 2025, according to a Tuesday Korean bourse filing.
The company has already approved the acquisition of the land from Siheung City for 94.9 billion won, with the final payment to be completed on Aug. 18.